Coronary Artery Disease, Ventricular Tachycardia
Conditions
Keywords
Keywords provided by Newmarket Electrophysiology Research Group Inc:, Ventricular tachycardia, Ventricular tachyarrhythmia, Ablation, Coronary artery disease, Ischemic heart disease, Amiodarone, Sotalol, Anti-Arrhythmia Agents, Therapeutic Uses, Pharmacologic Actions, Additional relevant MeSH terms:, Atrial Fibrillation, Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases, Pathologic Processes, Catheter Ablation, Radiofrequency
Brief summary
This study aims to compare antiarrhythmic drug therapy with catheter ablation using the SmartTOUCH catheter (Biosense Webster Inc.) as treatment for patients with ventricular tachycardia and coronary artery disease
Detailed description
This is a multicenter, randomized prospective cohort study to compare the impact of catheter ablation with antiarrhythmic drug therapy for treating patients with sustained ventricular tachycardia (VT) and coronary artery disease. Patients that meet all inclusion criteria and no exclusion criteria will be recruited to the study cohort. After baseline measurements are taken, patients will be randomized in a 2:1 fashion to either undergo radiofrequency catheter ablation or receive antiarrhythmic drug therapy (amiodarone or sotalol). The in-clinic appointments include: enrollment, baseline, intervention, and follow-up every three months for one year post-ablation. At each follow-up visit, electrogram (ECG) and Holter monitoring tests will be performed to measure any episodes of ventricular tachyarrhythmia. Furthermore, interrogation of the patient's implantable cardioverter defibrillator (ICD) will be performed at all follow-up visits to detect any episodes of ventricular tachyarrhythmia that required antitachycardia pacing (ATP) or shocks.
Interventions
PROCEDURECatheter Ablation
Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
DRUGMedical therapy (sotalol or amiodarone)
Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
Sponsors
Biosense Webster, Inc.
Newmarket Electrophysiology Research Group Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Sustained monomorphic VT (\>30 seconds, or requiring appropriate ICD therapy in patients with ICDs) * Documented ischemic heart disease with no further options for revascularization * Ability and willingness to give written informed consent to participate in the trial
Exclusion criteria
* VT in the setting of metabolic abnormalities or acute ischemia if coronary lesions suitable for revascularization are identified. * Acute ischemia with eligibility for revascularization * Significant peripheral arterial disease preventing transvascular access to the left ventricle. * Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy, Brugada syndrome, Long QT syndromes, dilated cardiomyopathy * Prior long term therapy with a Class III or Class IC antiarrhythmic agent (longer than 2 weeks) * Patient is or may be potentially pregnant * Patient has a mechanical heart valve * Myocardial infarction within the past 90 days * Stroke within the past 90 days * New York Heart Association (NYHA) functional class IV * Hemorrhagic manifestations, bleeding diathesis, or impairment of hemostasis * Lesions at risk of clinically significant bleeding (e.g., extensive cerebral infarction within the last 6 months, active peptic ulcer disease with recent bleeding) * Prior VT ablation procedure * Contraindication or allergy to contrast media, routine procedural medications or catheter materials * Contraindications to an interventional procedure * Life expectancy is less than 6 months * Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation * Untreated hypothyroidism or hyperthyroidism (euthyroid or thyroid hrt is acceptable) * Current enrolment in another investigational drug or device study * There are other conditions present that the investigator feels would be problematic or would restrict or limit the participation for the patient for the entire study period * Absolute contraindication to the use of heparin or warfarin * Documented intra-arterial thrombus, ventricular thrombus, (less than 6 months after detection of thrombus), tumor or other abnormality that precludes catheter introduction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence of Ventricular Tachycardia | 1 year | Number of any appropriate ATPs/shocks and/or presentations of sustained (\>30sec) VT on Holter or ECG recording at 3, 6, 9 and 12 months after intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total mortality | 1 year | Change in mortality status at 3, 6, 9 and 12 months after intervention |
| Sudden cardiac death | 1 year | Change in sudden cardiac death status at 3, 6, 9 and 12 months after intervention |
| Time to First Shock/ATP for VT or to First Presentation of Sustained VT | 1 year | Change in time to first ATP/shock or presentation of sustained (\>30sec) VT on Holter or ECG recording at 3, 6, 9 and 12 months after intervention |
| Number of hospitalizations | 1 year | Change in number of hospitalizations at 3, 6, 9 and 12 months after intervention |
| QOL measures | 1 year | Change in QOL measures at 6 and 12 months after intervention |
| Syncope | 1 year | Change in syncope status at 3, 6, 9 and 12 months after intervention |
Outcome results
None listed